PCRX at a glance
Pacira BioSciences, Inc. (PCRX, SEC CIK 1396814) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as August 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Pacira BioSciences, Inc. (PCRX) reported revenue of $726.4 million (up 3.6% from FY2024) and net income of $7.0 million. Diluted EPS was $0.16.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Pacira BioSciences, Inc. (PCRX) shares worth $639.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by SLONIN JONATHAN on August 17, 2026 of 3,040 shares at $23.23 per share.
- In the last 90 days, PCRX insiders reported 0 open-market purchases ($0) and 1 open-market sale ($71K) on Form 4, a net sale of $71K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $726.4M
- +3.6% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$71K
- 13F holders
- 29 funds
- $639.8M · −1 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Innovative non-opioid pain therapies including EXPAREL, ZILRETTA, and iovera° for postsurgical and osteoarthritis pain management
- New strategic plan "5x30" launched in Jan 2025 targeting 3M+ patients, double-digit revenue CAGR, 5% gross margin improvement, 5 clinical programs, 5 partnerships by 2030
- 2025 acquisition of GQ Bio Therapeutics expanding pipeline with gene therapy (PCRX-201) for osteoarthritis in Phase 2 development
- Net sales growth: EXPAREL $575.1M (2025) up from $549.0M (2024), ZILRETTA steady ~$117M, iovera° sales increased to $24.2M in 2025
- FDA approved label expansion for EXPAREL in Nov 2023 adding adductor canal and sciatic nerve blocks, broadening usage for over 3 million lower extremity procedures annually
Risk Factors
- Ongoing patent litigation against WhiteOak and Qilu threatens exclusive rights to EXPAREL and ZILRETTA, risking loss of patent protection and regulatory exclusivity
- Significant revenue concentration with EXPAREL at 79% and ZILRETTA at 16% of total 2025 revenue, exposing the company to commercial risks in these products
- Dependence on third-party cold-chain distributors for EXPAREL risks product spoilage if temperature controls fail, with limited insurance coverage for losses
- Intense competition from generic opioids and immediate-release steroids, including established generics for OA pain, may limit market share and pricing power
- Commercial success depends on obtaining timely hospital formulary approvals and physician prescribing, with delays or restrictions potentially reducing revenues
Management Discussion & Analysis
- Revenue $726.4M, up 4% YoY from $701.0M; EXPAREL $575.1M (+5%), ZILRETTA $116.6M (-1%), iovera° $24.2M (+6%)
- Gross margin 79% in 2025 vs 76% in 2024; cost of goods sold declined 12% to $149.7M
- Best segment: EXPAREL sales $575.1M (+5%), worst: ZILRETTA sales $116.6M (-1%)
- Cash used for share repurchases: $50M for 2 million shares in Q4 2025; no dividend or capex specifics disclosed
- 2026 outlook: Expanded Asian-Pacific access via LG Chem partnership with $2M upfront; tariff risks mitigated by recent US Supreme Court ruling; ongoing challenges from generic litigation and investment in R&D (44% increase)
AI summary of the PCRX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- iovera° divestiture closed July 31, 2026, generating $73.6 million cash proceeds
- Tariffs expected to pressure gross margins, including 15% on certain E.U. imports and 10% on U.K. imports
- PCRX-201 ASCEND Part A enrollment completed, with topline data expected by year-end 2026
- EXPAREL separate reimbursement expanded to approximately 150 million U.S. covered lives
Risk Factors
- New divestiture risk triggered by iovera° sale to Zimmer, including transition, indemnification, and contractual liabilities
- Most material update: potential milestone payments of $70.0 million depend on Zimmer’s performance and expire December 31, 2031
- Regulatory and commercial risk: milestone achievement depends on clinical and regulatory outcomes for iovera° products
- Operational risk: divestiture could divert management attention, disrupt operations, or increase costs
- Financial risk: failure to realize divestiture benefits or milestone payments could materially impair cash flows
AI summary of the PCRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Full results and management commentary furnished in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Pacira announced a Purchase Agreement on June 30, 2026, signaling a potentially material corporate transaction
- Exhibit 99.1 contains the agreement and transaction terms investors need to assess consideration, obligations, and strategic impact
Item 1.01: Entry into a Material Definitive Agreement
- Divestiture of iovera° cryoanalgesia business to Zimmer Biomet for up to $140.0 million
- $70.0 million upfront payment, subject to customary cash, receivables, debt, expenses and inventory adjustments
Item EX-99.1: Item EX-99.1
- Divestiture transfers Pacira’s iovera° rights to Zimmer Biomet, advancing Pacira’s transition toward an innovative biopharmaceutical company
- Pacira receives $70 million upfront and up to $70 million in revenue-based milestones through December 31, 2031
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stockholders approved ESPP expansion, reserving 800,000 additional common shares for employee purchases
- Increased share authorization creates potential future dilution but supports employee equity participation
Item 8.01: Other Events
- Pacira issued an Annual Meeting press release on June 9, 2026
- Exhibit 99.1 contains the substantive meeting-related information for investor review
Item EX-99.1: Item EX-99.1
- Stockholders preliminarily elected all three Pacira nominees: Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans
- Board outcome supports management’s ability to pursue Pacira’s 5x30 strategy and broader non-opioid pain portfolio
Item 5.07: Submission of Matters to a Vote of Security Holders
- Company nominees won all three Class III director seats; DOMA Perpetual Capital Management nominees were rejected
- Samit Hirawat and Thomas Wiggans received 27,950,304 and 28,044,841 votes, respectively
AI summaries of PCRX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PCRX
Don't miss the next PCRX filing
- Alerts as it files. A push when PCRX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PCRX, by share count.
- Ask anything. An AI agent that reads every PCRX filing and answers with sources.
PCRX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| SLONIN JONATHAN | Sell | Aug 17, 2026 | 3,040 | $23.23 |
| RIKER LAUREN | Sell | Jun 11, 2026 | 6,115 | $23.50 |
| Brege Laura | A | Jun 10, 2026 | 10,891 | - |
| Froimson Mark | A | Jun 10, 2026 | 10,891 | - |
| BIGAL MARCELO | A | Jun 10, 2026 | 10,891 | - |
| Brege Laura | A | Jun 10, 2026 | 6,405 | - |
| BIGAL MARCELO | A | Jun 10, 2026 | 6,405 | - |
| Hirawat Samit | A | Jun 10, 2026 | 6,405 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $701.0M | $726.4M |
| Operating Income | - | -$73.4M | $19.2M |
| Net Income | $42.0M | -$99.6M | $7.0M |
| Op. Margin | - | -10.5% | 2.6% |
| Net Margin | - | -14.2% | 1.0% |
| Balance Sheet | |||
| Total Assets | $1.6B | $1.6B | $1.3B |
| Equity | - | $778.3M | $693.1M |
| ROE | - | -12.8% | 1.0% |
| Per Share | |||
| EPS | $0.89 | $-2.15 | $0.16 |
| Cash Flow | |||
| Operating CF | - | $189.4M | $152.0M |
| CapEx | $15.2M | $10.6M | $15.3M |
Source: XBRL data in Pacira BioSciences, Inc. (PCRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PCRX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $639.8M |
| Q1 2026 | 30 | $581.5M |
| Q4 2025 | 28 | $675.6M |
| Q3 2025 | 28 | $696.9M |
| Q2 2025 | 29 | $678.2M |
| Q1 2025 | 26 | $532.1M |
| Q4 2024 | 21 | $340.2M |
| Q3 2024 | 19 | $184.1M |
- Two Sigma Investments+197.8K (+38%)
- Millennium Management+178.1K (+312%)
- State Street Corp+140.4K (+7%)
- FMR LLC (Fidelity)+123.5K (+132%)
- JPMorgan Chase & Co+106.3K (+44%)
- Citadel Advisors LLC−635.1K (-80%)
- Morgan Stanley−247.9K (-18%)
- Prudential Financial−103.2K (-56%)
- Vanguard Portfolio Management LLC−95.0K (-4%)
- Vanguard Capital Management LLC−92.5K (-5%)
- Franklin Resources−32.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 210 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PCRX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 18, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| SC 13G | May 1, 2026 | - | - | |
| SC 13G | May 1, 2026 | - | - | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
| SC 13G | Apr 9, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PCRX SEC filings: frequently asked questions
Are PCRX insiders buying or selling?
In the last 90 days, Pacira BioSciences, Inc. (PCRX) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $70,619 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PCRX stock?
As of June 30, 2026, the largest Pacira BioSciences, Inc. (PCRX) holders among the 13F filers tracked by SignalX were BlackRock ($170.1 million), Vanguard Portfolio Management LLC ($61.0 million), Dimensional Fund Advisors ($53.4 million), State Street Corp ($52.3 million), D.E. Shaw & Co ($49.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PCRX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Pacira BioSciences, Inc. (PCRX) reported revenue of $726.4 million (up 3.6% from FY2024) and net income of $7.0 million. Diluted EPS was $0.16. The figures come from the XBRL data in the 10-K.
What are the main risks in PCRX's latest 10-K?
In the 10-K filed February 26, 2026, Pacira BioSciences, Inc. (PCRX) flagged: Ongoing patent litigation against WhiteOak and Qilu threatens exclusive rights to EXPAREL and ZILRETTA, risking loss of patent protection and regulatory exclusivity. Significant revenue concentration with EXPAREL at 79% and ZILRETTA at 16% of total 2025 revenue, exposing the company to commercial risks in these products. (AI summary of the Risk Factors section.)
What did PCRX report in its latest 8-K?
Pacira BioSciences, Inc. (PCRX) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
What are the latest PCRX SEC filings?
Pacira BioSciences, Inc. (PCRX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on August 18, 2026.
What is PCRX's SEC CIK number?
Pacira BioSciences, Inc. (PCRX)'s SEC Central Index Key (CIK) is 1396814. EDGAR lists every PCRX filing under that number.
Ask anything about PCRX
The research agent reads PCRX's filings, financials, insider trades and 13F holders, then answers with sources.